Miriam R. Elman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Miriam R. Elman has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
- Jessina C. McGregor
Department of Pharmacy Practice, College of Pharmacy, Oregon State University, Portland, OR, USA
7 shared publications - David T. Bearden
Department of Pharmacy Practice, College of Pharmacy, Oregon State University, Portland, Oregon
5 shared publications - Ahmad Masri
Knight Cardiovascular Institute, Oregon Health and Science University
4 shared publications Hailey Volk
Knight Cardiovascular Institute, OHSU
3 shared publicationsAngelica T. Mejia
Knight Cardiovascular Institute, OHSU
2 shared publications- Daniel Kamna
Knight Cardiovascular Institute, Oregon Health and Science University
2 shared publications
Latest Publications
- Open Access
- 4 November 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (21) , e042488
Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy
Background: Our objective was to assess real‐world outcomes and health care use associated with commercial mavacamten use in patients with obstructive hypertrophic cardiomyopathy. Methods: We used the Symphony Dataverse to study patients receiving mavacamten between May 25, 2022 and June 30, 2024. Safety outcomes were prespecified. Results: We included 2440 patients and 18 494 mavacamten dispenses (63% women, median age 66 years [interquartile range {IQR}, 55–73]). Patients were followed for a median of 3037.0 days (IQR, 2808–3221) before mavacamten initiation and for 240 days (IQR, 117–407) on mavacamten. Atrial fibrillation or flutter (AF/AFL) at baseline were present in 536 (22%) of patients, whereas new‐onset AF/AFL requiring therapy occurred in 125 patients (5%) and new heart failure (HF) in 100 patients (4%). During follow‐up, 154 patients (6%) received new dispenses of loop diuretics, 102 (4%) oral anticoagulants, 78 (3%) amiodarone, 17 (0.7%) sotalol, and 6 (0.2%) dofetilide. There was a total of 306 patients (13%) with 428 acute care episodes (most common claims were HF (n=80, 26%), AF (n=74, 24%), and AFL (n=16, 5%)). Predictors of outcomes (new HF, new AF/AFL, ventricular tachycardia, or transient ischemic attack/stroke claim) were age at mavacamten start, obesity, transient ischemic attack/stroke history, and residence in the Western versus Southern United States. Conclusions: Over an 8‐month median follow‐up on mavacamten in patients with obstructive hypertrophic cardiomyopathy, new AF/AFL and HF occurred in 5% and 4%, respectively. Further work is needed to better understand the expected incidence of AF/AFL, HF, and other long‐term outcomes of mavacamten treatment in obstructive hypertrophic cardiomyopathy.
- 4 November 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (21) , e042488
Open AccessCharacteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy
Background: Our objective was to assess real‐world outcomes and health care use associated with commercial mavacamten use in patients with obstructive hypertrophic cardiomyopathy. Methods: We used the Symphony Dataverse to study patients receiving mavacamten between May 25, 2022 and June 30, 2024. Safety outcomes were prespecified. Results: We included 2440 patients and 18 494 mavacamten dispenses (63% women, median age 66 years [interquartile range {IQR}, 55–73]). Patients were followed for a median of 3037.0 days (IQR, 2808–3221) before mavacamten initiation and for 240 days (IQR, 117–407) on mavacamten. Atrial fibrillation or flutter (AF/AFL) at baseline were present in 536 (22%) of patients, whereas new‐onset AF/AFL requiring therapy occurred in 125 patients (5%) and new heart failure (HF) in 100 patients (4%). During follow‐up, 154 patients (6%) received new dispenses of loop diuretics, 102 (4%) oral anticoagulants, 78 (3%) amiodarone, 17 (0.7%) sotalol, and 6 (0.2%) dofetilide. There was a total of 306 patients (13%) with 428 acute care episodes (most common claims were HF (n=80, 26%), AF (n=74, 24%), and AFL (n=16, 5%)). Predictors of outcomes (new HF, new AF/AFL, ventricular tachycardia, or transient ischemic attack/stroke claim) were age at mavacamten start, obesity, transient ischemic attack/stroke history, and residence in the Western versus Southern United States. Conclusions: Over an 8‐month median follow‐up on mavacamten in patients with obstructive hypertrophic cardiomyopathy, new AF/AFL and HF occurred in 5% and 4%, respectively. Further work is needed to better understand the expected incidence of AF/AFL, HF, and other long‐term outcomes of mavacamten treatment in obstructive hypertrophic cardiomyopathy.
- Open Access
- 23 September 2025
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 276, 112894
Preferences for clinical trial participation among people who use drugs in rural Oregon and Appalachian Ohio
- 23 September 2025
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 276, 112894
Open AccessPreferences for clinical trial participation among people who use drugs in rural Oregon and Appalachian Ohio
- Open Access
- 15 July 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (14) , e040655
Cardiovascular Hospitalizations Burden Following Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy
Background: Longer‐term morbidity post septal myectomy (SM) in obstructive hypertrophic cardiomyopathy has not been well characterized at a national level. We aimed to investigate the nonfatal longer‐term post‐SM outcomes from a national all‐payer individual‐level claims. Methods: The Symphony Health Claims database (2016–2021) was analyzed to identify all adult patients with obstructive hypertrophic cardiomyopathy who underwent SM in the United States and had at least 1 claim within 120 days before SM. The primary outcome was cardiovascular hospitalizations (CVH) starting >30 days post‐SM. Results: A total of 5324 patient (median age 62.0 [52.0–70.0], 53.2% female, 70% commercial insurance) underwent SM and 95.8% were followed >30 days post SM. During 2.7 (1.2–4.2) years median follow‐up, CVH occurred in 46.7% (80% of CVH within 16 months of SM). CVH for new atrial fibrillation/flutter was 25.4%, ventricular arrhythmias 9.7%, syncope 9.3%, myocardial infarction 5.2%, cardiac arrest 1.6%, ventricular septal defect 0.9%, and need for advanced heart failure therapy 0.6%. Repeat SM was required in 43 patients (0.8%). The strongest predictors of CVH post SM were presence of an implantable cardioverter‐defibrillator at baseline (adjusted odds ratio [aOR], 1.72 [95% CI, 1.50–1.97], P P P <0.001). Conclusions: Over a 3‐year period, SM for obstructive hypertrophic cardiomyopathy was associated with a high burden of CVH. Investigating the drivers of these events and strategies to mitigate the high incidence of intermediate and long‐term nonfatal complications post SM will help improve the care of patients with obstructive hypertrophic cardiomyopathy.
- 15 July 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (14) , e040655
Open AccessCardiovascular Hospitalizations Burden Following Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy
Background: Longer‐term morbidity post septal myectomy (SM) in obstructive hypertrophic cardiomyopathy has not been well characterized at a national level. We aimed to investigate the nonfatal longer‐term post‐SM outcomes from a national all‐payer individual‐level claims. Methods: The Symphony Health Claims database (2016–2021) was analyzed to identify all adult patients with obstructive hypertrophic cardiomyopathy who underwent SM in the United States and had at least 1 claim within 120 days before SM. The primary outcome was cardiovascular hospitalizations (CVH) starting >30 days post‐SM. Results: A total of 5324 patient (median age 62.0 [52.0–70.0], 53.2% female, 70% commercial insurance) underwent SM and 95.8% were followed >30 days post SM. During 2.7 (1.2–4.2) years median follow‐up, CVH occurred in 46.7% (80% of CVH within 16 months of SM). CVH for new atrial fibrillation/flutter was 25.4%, ventricular arrhythmias 9.7%, syncope 9.3%, myocardial infarction 5.2%, cardiac arrest 1.6%, ventricular septal defect 0.9%, and need for advanced heart failure therapy 0.6%. Repeat SM was required in 43 patients (0.8%). The strongest predictors of CVH post SM were presence of an implantable cardioverter‐defibrillator at baseline (adjusted odds ratio [aOR], 1.72 [95% CI, 1.50–1.97], P P P <0.001). Conclusions: Over a 3‐year period, SM for obstructive hypertrophic cardiomyopathy was associated with a high burden of CVH. Investigating the drivers of these events and strategies to mitigate the high incidence of intermediate and long‐term nonfatal complications post SM will help improve the care of patients with obstructive hypertrophic cardiomyopathy.
- Open Access
Characteristics and Outcomes of Mavacamten Use In 2440 Patients with Obstructive Hypertrophic Cardiomyopathy
Aims: To assess real-world characteristics, outcomes, and healthcare utilization associated with commercial mavacamten use in patients with oHCM. Methods and Results: We used the Symphony Dataverse to study patients receiving mavacamten between May 25, 2022 and June 30, 2024. Safety outcomes were prespecified and individual hospital-level claims manually reviewed to categorize cardiovascular hospitalizations. We included 2,440 patients and 18,494 mavacamten dispenses (63% females, median age 66 years [Interquartile range (IQR): 55, 73]). Patients were followed for a median of 3,037.0 days (IQR: 2,808, 3,221) prior to mavacamten initiation, and for 240 days (IQR: 117, 407) on mavacamten. Atrial fibrillation or flutter (AF/AFL) at baseline were present in 536 (22%) of patients, while new-onset AF/AFL requiring therapy occurred in 125 patients (5%) and new heart failure (HF) in 100 patients (4%). During follow-up, 154 patients (6%) received new dispenses of loop diuretics, 102 (4%) oral anticoagulants, 78 (3%) amiodarone, 17 (0.7%) sotalol, and 6 (0.2%) dofetilide. There was a total of 306 patients (13%) with 428 acute care episodes (most common claims were HF (n= 80, 26%), AF (n=74, 24%), and AFL (n= 16, 5%)). Predictors of safety outcomes (new HF, new AF/AFL, ventricular tachycardia, or transient ischemic attack [TIA]/stroke claim) were: age at mavacamten start, obesity, and TIA/stroke history. Conclusion: With 8 month median follow-up in this study, healthcare utilization for patients on mavacamten appeared substantial. New AF/AFL and HF occurred in 5% and 4%, respectively. Further work is needed to understand longer-term outcomes of mavacamten use in oHCM.
Open AccessCharacteristics and Outcomes of Mavacamten Use In 2440 Patients with Obstructive Hypertrophic Cardiomyopathy
Aims: To assess real-world characteristics, outcomes, and healthcare utilization associated with commercial mavacamten use in patients with oHCM. Methods and Results: We used the Symphony Dataverse to study patients receiving mavacamten between May 25, 2022 and June 30, 2024. Safety outcomes were prespecified and individual hospital-level claims manually reviewed to categorize cardiovascular hospitalizations. We included 2,440 patients and 18,494 mavacamten dispenses (63% females, median age 66 years [Interquartile range (IQR): 55, 73]). Patients were followed for a median of 3,037.0 days (IQR: 2,808, 3,221) prior to mavacamten initiation, and for 240 days (IQR: 117, 407) on mavacamten. Atrial fibrillation or flutter (AF/AFL) at baseline were present in 536 (22%) of patients, while new-onset AF/AFL requiring therapy occurred in 125 patients (5%) and new heart failure (HF) in 100 patients (4%). During follow-up, 154 patients (6%) received new dispenses of loop diuretics, 102 (4%) oral anticoagulants, 78 (3%) amiodarone, 17 (0.7%) sotalol, and 6 (0.2%) dofetilide. There was a total of 306 patients (13%) with 428 acute care episodes (most common claims were HF (n= 80, 26%), AF (n=74, 24%), and AFL (n= 16, 5%)). Predictors of safety outcomes (new HF, new AF/AFL, ventricular tachycardia, or transient ischemic attack [TIA]/stroke claim) were: age at mavacamten start, obesity, and TIA/stroke history. Conclusion: With 8 month median follow-up in this study, healthcare utilization for patients on mavacamten appeared substantial. New AF/AFL and HF occurred in 5% and 4%, respectively. Further work is needed to understand longer-term outcomes of mavacamten use in oHCM.
- 16 May 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (10) , e028693
Hospital Procedural Volume and Clinical Outcomes Following Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy
Background: Prior national data showed a substantial in‐hospital mortality in septal myectomy (SM) with an inverse volume–outcomes relationship. This study sought to assess the contemporary outcomes of septal reduction therapy and volume–outcome relationship in obstructive hypertrophic cardiomyopathy. Methods and Results: All septal reduction therapy admissions between 2010 to 2019 in the United States were analyzed using the National Readmission Databases. Hospitals were stratified into tertiles of low‐, medium‐, and high‐volume based on annualized procedural volume of alcohol septal ablation and SM. Of 19 007 patients with obstructive hypertrophic cardiomyopathy who underwent septal reduction therapy, 12 065 (63%) had SM. Two‐thirds of hospitals performed ≤5 SM or alcohol septal ablation annually. In all SM encounters, 482 patients (4.0%) died in‐hospital post‐SM. In‐hospital mortality was P =0.003; adjusted odds ratio [aOR], 2.86 [95% CI, 1.70–4.80], P =0.001), adverse in‐hospital events (21.30% versus 18.0% versus 12.6%, P =0.001; aOR, 1.88 [95% CI, 1.45–2.43], P =0.001), and 30‐day readmission (17.1% versus 12.9% versus 9.7%, P =0.001; adjusted hazard ratio, 1.53 [95% CI, 1.27–1.96], P =0.001) were significantly higher in low‐ versus high‐volume hospitals. For alcohol septal ablation, the incidence of in‐hospital death and all other outcomes did not differ by hospital volume. Conclusions: In‐hospital SM mortality was 4% with an inverse volume‐mortality relationship. Mortality post‐alcohol septal ablation was similar across all volume tertiles. Morbidity associated with SM was substantial across all volume tertiles.
- 16 May 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (10) , e028693
Hospital Procedural Volume and Clinical Outcomes Following Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy
Background: Prior national data showed a substantial in‐hospital mortality in septal myectomy (SM) with an inverse volume–outcomes relationship. This study sought to assess the contemporary outcomes of septal reduction therapy and volume–outcome relationship in obstructive hypertrophic cardiomyopathy. Methods and Results: All septal reduction therapy admissions between 2010 to 2019 in the United States were analyzed using the National Readmission Databases. Hospitals were stratified into tertiles of low‐, medium‐, and high‐volume based on annualized procedural volume of alcohol septal ablation and SM. Of 19 007 patients with obstructive hypertrophic cardiomyopathy who underwent septal reduction therapy, 12 065 (63%) had SM. Two‐thirds of hospitals performed ≤5 SM or alcohol septal ablation annually. In all SM encounters, 482 patients (4.0%) died in‐hospital post‐SM. In‐hospital mortality was P =0.003; adjusted odds ratio [aOR], 2.86 [95% CI, 1.70–4.80], P =0.001), adverse in‐hospital events (21.30% versus 18.0% versus 12.6%, P =0.001; aOR, 1.88 [95% CI, 1.45–2.43], P =0.001), and 30‐day readmission (17.1% versus 12.9% versus 9.7%, P =0.001; adjusted hazard ratio, 1.53 [95% CI, 1.27–1.96], P =0.001) were significantly higher in low‐ versus high‐volume hospitals. For alcohol septal ablation, the incidence of in‐hospital death and all other outcomes did not differ by hospital volume. Conclusions: In‐hospital SM mortality was 4% with an inverse volume‐mortality relationship. Mortality post‐alcohol septal ablation was similar across all volume tertiles. Morbidity associated with SM was substantial across all volume tertiles.
- Open Access
- 4 March 2023
- Published by Elsevier in SSM - Population Health
- Vol. 22, 101375
Racial, ethnic, and socioeconomic disparities in trajectories of morbidity accumulation among older Americans
- 4 March 2023
- Published by Elsevier in SSM - Population Health
- Vol. 22, 101375
Open AccessRacial, ethnic, and socioeconomic disparities in trajectories of morbidity accumulation among older Americans
- Open Access
- 1 October 2021
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 17 (10) , 1787-1798
Postbariatric hypoglycemia: symptom patterns and associated risk factors in the Longitudinal Assessment of Bariatric Surgery study
- 1 October 2021
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 17 (10) , 1787-1798
Open AccessPostbariatric hypoglycemia: symptom patterns and associated risk factors in the Longitudinal Assessment of Bariatric Surgery study
- 20 June 2019
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 40 (8) , 863-871
Healthcare-associated urinary tract infections with onset post hospital discharge
Objective: Current surveillance for healthcare-associated (HA) urinary tract infection (UTI) is focused on catheter-associated infection with hospital onset (HO-CAUTI), yet this surveillance does not represent the full burden of HA-UTI to patients. Our objective was to measure the incidence of potentially HA, community-onset (CO) UTI in a retrospective cohort of hospitalized patients.Design: Retrospective cohort study.Setting: Academic, quaternary care, referral center.Patients: Hospitalized adults at risk for HA-UTI from May 2009 to December 2011 were included.Methods: Patients who did not experience a UTI during the index hospitalization were followed for 30 days post discharge to identify cases of potentially HA-CO UTI.Results: We identified 3,273 patients at risk for potentially HA-CO UTI. The incidence of HA-CO UTI in the 30 days post discharge was 29.8 per 1,000 patients. Independent risk factors of HA-CO UTI included paraplegia or quadriplegia (adjusted odds ratio [aOR], 4.6; 95% confidence interval [CI], 1.2–18.0), indwelling catheter during index hospitalization (aOR, 1.5; 95% CI, 1.0–2.3), prior piperacillin-tazobactam prescription (aOR, 2.3; 95% CI, 1.1–4.5), prior penicillin class prescription (aOR, 1.7; 95% CI, 1.0–2.8), and private insurance (aOR, 0.6; 95% CI, 0.4–0.9).Conclusions: HA-CO UTI may be common within 30 days following hospital discharge. These data suggest that surveillance efforts may need to be expanded to capture the full burden to patients and better inform antibiotic prescribing decisions for patients with a history of hospitalization.
- 20 June 2019
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 40 (8) , 863-871
Healthcare-associated urinary tract infections with onset post hospital discharge
Objective: Current surveillance for healthcare-associated (HA) urinary tract infection (UTI) is focused on catheter-associated infection with hospital onset (HO-CAUTI), yet this surveillance does not represent the full burden of HA-UTI to patients. Our objective was to measure the incidence of potentially HA, community-onset (CO) UTI in a retrospective cohort of hospitalized patients.Design: Retrospective cohort study.Setting: Academic, quaternary care, referral center.Patients: Hospitalized adults at risk for HA-UTI from May 2009 to December 2011 were included.Methods: Patients who did not experience a UTI during the index hospitalization were followed for 30 days post discharge to identify cases of potentially HA-CO UTI.Results: We identified 3,273 patients at risk for potentially HA-CO UTI. The incidence of HA-CO UTI in the 30 days post discharge was 29.8 per 1,000 patients. Independent risk factors of HA-CO UTI included paraplegia or quadriplegia (adjusted odds ratio [aOR], 4.6; 95% confidence interval [CI], 1.2–18.0), indwelling catheter during index hospitalization (aOR, 1.5; 95% CI, 1.0–2.3), prior piperacillin-tazobactam prescription (aOR, 2.3; 95% CI, 1.1–4.5), prior penicillin class prescription (aOR, 1.7; 95% CI, 1.0–2.8), and private insurance (aOR, 0.6; 95% CI, 0.4–0.9).Conclusions: HA-CO UTI may be common within 30 days following hospital discharge. These data suggest that surveillance efforts may need to be expanded to capture the full burden to patients and better inform antibiotic prescribing decisions for patients with a history of hospitalization.
- 21 May 2019
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 30 (9) , 1636-1643
Effectiveness of dual external direct current cardioversion for initial cardioversion in atrial fibrillation
Introduction: Dual external direct current cardioversion (dual‐DCCV) is a rhythm control strategy for persistent atrial fibrillation (AF), involving simultaneous delivery of two shocks from two defibrillators. The long‐term effectiveness of this approach has not been studied in the biphasic cardioversion era.Methods: Seventy‐seven consecutive patients at a single center were identified to receive dual‐DCCV at the time of their initial cardioversion for AF, when maximum output standard external direct current cardioversion failed in two vectors. Logistic regression was used to analyze risk factors for dual‐DCCV in a historical control group of 77 patients undergoing standard cardioversion and Cox proportional hazard models were used to compare time to AF recurrence.Results: The dual‐DCCV group had a significantly larger body mass index (BMI), but similar AF duration and left atrial size as controls. Multivariable logistic regression revealed that BMI and absence of prior paroxysmal AF were risk factors for dual‐DCCV (P < 0.05). There was no difference observed between dual‐DCCV and control groups (adjusted hazard ratio = 0.57; P = .12) after adjusting for number of shocks and age. Transient hypoxia was the only acute complication in either group (P > .999).Conclusion: Dual‐DCCV appears to be a safe and effective cardioversion strategy for patients with AF. The need for dual‐DCCV in the treatment of AF appears to be influenced more by body habitus than atrial substrate.
- 21 May 2019
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 30 (9) , 1636-1643
Effectiveness of dual external direct current cardioversion for initial cardioversion in atrial fibrillation
Introduction: Dual external direct current cardioversion (dual‐DCCV) is a rhythm control strategy for persistent atrial fibrillation (AF), involving simultaneous delivery of two shocks from two defibrillators. The long‐term effectiveness of this approach has not been studied in the biphasic cardioversion era.Methods: Seventy‐seven consecutive patients at a single center were identified to receive dual‐DCCV at the time of their initial cardioversion for AF, when maximum output standard external direct current cardioversion failed in two vectors. Logistic regression was used to analyze risk factors for dual‐DCCV in a historical control group of 77 patients undergoing standard cardioversion and Cox proportional hazard models were used to compare time to AF recurrence.Results: The dual‐DCCV group had a significantly larger body mass index (BMI), but similar AF duration and left atrial size as controls. Multivariable logistic regression revealed that BMI and absence of prior paroxysmal AF were risk factors for dual‐DCCV (P < 0.05). There was no difference observed between dual‐DCCV and control groups (adjusted hazard ratio = 0.57; P = .12) after adjusting for number of shocks and age. Transient hypoxia was the only acute complication in either group (P > .999).Conclusion: Dual‐DCCV appears to be a safe and effective cardioversion strategy for patients with AF. The need for dual‐DCCV in the treatment of AF appears to be influenced more by body habitus than atrial substrate.
- 1 March 2018
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 39 (5) , 578-583
Empiric Antibiotic Prescribing Decisions Among Medical Residents: The Role of the Antibiogram
OBJECTIVE: To assess general medical residents’ familiarity with antibiograms using a self-administered surveyDESIGN: Cross-sectional, single-center surveyPARTICIPANTS: Residents in internal medicine, family medicine, and pediatrics at an academic medical centerMETHODS: Participants were administered an anonymous survey at our institution during regularly scheduled educational conferences between January and May 2012. Questions collected data regarding demographics, professional training; further open-ended questions assessed knowledge and use of antibiograms regarding possible pathogens, antibiotic regimens, and prescribing resources for 2 clinical vignettes; a series of directed, closed-ended questions followed. Bivariate analyses to compare responses between residency programs were performed.RESULTS: Of 122 surveys distributed, 106 residents (87%) responded; internal medicine residents accounted for 69% of responses. More than 20% of residents could not accurately identify pathogens to target with empiric therapy or select therapy with an appropriate spectrum of activity in response to the clinical vignettes; correct identification of potential pathogens was not associated with selecting appropriate therapy. Only 12% of respondents identified antibiograms as a resource when prescribing empiric antibiotic therapy for scenarios in the vignettes, with most selecting the UpToDate online clinical decision support resource or The Sanford Guide. When directly questioned, 89% reported awareness of institutional antibiograms, but only 70% felt comfortable using them and only 44% knew how to access them.CONCLUSIONS: When selecting empiric antibiotics, many residents are not comfortable using antibiograms as part of treatment decisions. Efforts to improve antibiotic use may benefit from residents being given additional education on both infectious diseases pharmacotherapy and antibiogram utilization.Infect Control Hosp Epidemiol 2018;39:578–583
- 1 March 2018
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 39 (5) , 578-583
Empiric Antibiotic Prescribing Decisions Among Medical Residents: The Role of the Antibiogram
OBJECTIVE: To assess general medical residents’ familiarity with antibiograms using a self-administered surveyDESIGN: Cross-sectional, single-center surveyPARTICIPANTS: Residents in internal medicine, family medicine, and pediatrics at an academic medical centerMETHODS: Participants were administered an anonymous survey at our institution during regularly scheduled educational conferences between January and May 2012. Questions collected data regarding demographics, professional training; further open-ended questions assessed knowledge and use of antibiograms regarding possible pathogens, antibiotic regimens, and prescribing resources for 2 clinical vignettes; a series of directed, closed-ended questions followed. Bivariate analyses to compare responses between residency programs were performed.RESULTS: Of 122 surveys distributed, 106 residents (87%) responded; internal medicine residents accounted for 69% of responses. More than 20% of residents could not accurately identify pathogens to target with empiric therapy or select therapy with an appropriate spectrum of activity in response to the clinical vignettes; correct identification of potential pathogens was not associated with selecting appropriate therapy. Only 12% of respondents identified antibiograms as a resource when prescribing empiric antibiotic therapy for scenarios in the vignettes, with most selecting the UpToDate online clinical decision support resource or The Sanford Guide. When directly questioned, 89% reported awareness of institutional antibiograms, but only 70% felt comfortable using them and only 44% knew how to access them.CONCLUSIONS: When selecting empiric antibiotics, many residents are not comfortable using antibiograms as part of treatment decisions. Efforts to improve antibiotic use may benefit from residents being given additional education on both infectious diseases pharmacotherapy and antibiogram utilization.Infect Control Hosp Epidemiol 2018;39:578–583